PMID- 29416660
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 9
IP  - 1
DP  - 2018 Jan 2
TI  - FoxM1 is a promising candidate target in the treatment of breast cancer.
PG  - 842-852
LID - 10.18632/oncotarget.23182 [doi]
AB  - Forkhead box protein M1(FoxM1) is a member of forkhead superfamily transcription 
      factors. Emerging evidences have progressively contributed to our understanding 
      on a central role of FoxM1 in human cancers. However, perspectives on the 
      function of FoxM1 in breast cancer (BC) remain conflicting, and mostly were from 
      basic research. Here, we explored the expression profile and prognostic values of 
      FoxM1 based on analysis of pooled clinical datasets derived from online 
      accessible databases, including ONCOMINE, Breast Cancer Gene-Expression Miner 
      v4.0, and Kaplan-Meier plotter. It was found that, FoxM1 mRNA expression was 
      significantly higher in breast tumor versus normal control. FoxM1expression 
      profile presented a distinct pattern in different molecular subtypes of BC 
      patients. Higher expression of FoxM1 was correlated to low mRNA expression of 
      estrogen receptor 1 (ESR1), erb-B2 receptor tyrosine kinase 2 (ERBB2), and was 
      inversely associated with the expression of classical luminal regulators forkhead 
      box protein A1 (FoxA1) and GATA binding protein 3 (GATA3). Elevated FoxM1 
      expression predicted shorter distance metastasis free survival (DMFS) in BC 
      patients, particularly with estrogen receptor (ER) positive and Luminal A, 
      Luminal B subtypes of BC. More interestingly, elevated FoxM1 expression predicted 
      poor survival in breast cancer patients, especially in the ER (+), progesterone 
      receptor (PR) (+) subgroups and BC patients received adjuvant chemotherapy only 
      or treated with tamoxifen only. These results implied that FoxM1 is an essential 
      prognostic factor and promising candidate target in the treatment of breast 
      cancer.
FAU - Lu, Xiao-Feng
AU  - Lu XF
AD  - Department of Breast and Thyroid Surgery, The First Affiliated Hospital of 
      Shantou University Medical College, Shantou, China.
FAU - Zeng, De
AU  - Zeng D
AD  - Department of Medical Oncology, Cancer Hospital of Shantou University Medical 
      College, Shantou, China.
FAU - Liang, Wei-Quan
AU  - Liang WQ
AD  - Department of Breast and Thyroid Surgery, The First Affiliated Hospital of 
      Shantou University Medical College, Shantou, China.
FAU - Chen, Chun-Fa
AU  - Chen CF
AD  - Department of Breast and Thyroid Surgery, The First Affiliated Hospital of 
      Shantou University Medical College, Shantou, China.
FAU - Sun, Shu-Ming
AU  - Sun SM
AD  - Department of Breast and Thyroid Surgery, The First Affiliated Hospital of 
      Shantou University Medical College, Shantou, China.
FAU - Lin, Hao-Yu
AU  - Lin HY
AD  - Department of Breast and Thyroid Surgery, The First Affiliated Hospital of 
      Shantou University Medical College, Shantou, China.
LA  - eng
PT  - Journal Article
DEP - 20171212
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5787517
OTO - NOTNLM
OT  - FoxM1
OT  - breast cancer
OT  - prognostic values
COIS- CONFLICTS OF INTEREST The authors declare no conflicts of interest.
EDAT- 2018/02/09 06:00
MHDA- 2018/02/09 06:01
PMCR- 2018/01/02
CRDT- 2018/02/09 06:00
PHST- 2017/08/28 00:00 [received]
PHST- 2017/11/16 00:00 [accepted]
PHST- 2018/02/09 06:00 [entrez]
PHST- 2018/02/09 06:00 [pubmed]
PHST- 2018/02/09 06:01 [medline]
PHST- 2018/01/02 00:00 [pmc-release]
AID - 23182 [pii]
AID - 10.18632/oncotarget.23182 [doi]
PST - epublish
SO  - Oncotarget. 2017 Dec 12;9(1):842-852. doi: 10.18632/oncotarget.23182. eCollection 
      2018 Jan 2.